The Muro and Muzykantov groups have used targeted therapeutics to endothelial ICAM-1 in vitro and in vivo for treatment of lysosomal storage diseases, acute and chronic respiratory diseases, and other vascular diseases [32,46,47,48]. Here, ICAM1 is linked to lysosomal storage disease.